Genmab — November 2018
-
-
Jeps..Du må gerne stille flere - og det må alle I andre også godt.
-
Genmab har givet os længere spørgetid. Den skal vi gerne fylde ud.
-
very true @Bulder , and the comments on/around MAIA seem to imply this is really, really good data. I mean, I know there are complaints sometimes that Jan is too positive, but he is certainly not stupid and he knows how to interpret data. And I think this time he said it calmly and with solid arguments.
-
GENMAB/HANDELSBANKEN: SKÆRER KURSMÅLET 100 KR. EFTER REGNSKAB
-
Årsagen er, at banken indbygger en lidt kortere behandlingstid med Darzalex i sine salgsestimater for Genmabs kræftmiddel.
- Det faktiske salg af Darzalex tyder på, at behandlingens virkelige varighed er kortere end tidligere afspejlet i vores tal, og vi reviderer derfor vores prognoser i overensstemmelse hermed, skriver Handelsbanken i sin morgenkommentar, Børsnyt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind